Sun Pharma’s Ilumya Hits Key Milestone—What It Means for Millions with Joint Disease

Unknown Apr 02, 2026 900 Views

Sun Pharma's Ilumya (tildrakizumab-asmn) posted promising Phase 2b trial results that will pave the way for a possible US filing for the treatment of psoriatic arthritis. The medicine, already approved for plaque psoriasis, demonstrated robust efficacy in alleviating joint symptoms. ...